Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Kantarjian
Hagop
H
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. hkantarj@mdanderson.org
Schiffer
Charles
C
Jones
Dan
D
Cortes
Jorge
J
D002871:Chromosome Banding; D004252:DNA Mutational Analysis; D016903:Drug Monitoring; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl; D015321:Gene Rearrangement; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
D004791:Enzyme Inhibitors; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl